Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Abcellera Biologics Inc (NQ: ABCL ) 2.470 -0.100 (-3.89%) Streaming Delayed Price Updated: 3:15 PM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Abcellera Biologics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > AbCellera Reports Q3 2021 Business Results November 09, 2021 From AbCellera Biologics Inc. Via Business Wire How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed November 09, 2021 Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last... Via Benzinga AbCellera Announces Virtual Presentations at Investor Conferences in November November 04, 2021 From AbCellera Biologics Inc. Via Business Wire Why AbCellera Biologics Stock Sank 21.6% in October November 04, 2021 The biotech is now down roughly 56% across 2021's trading. Via The Motley Fool Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19 November 02, 2021 From AbCellera Biologics Inc. Via Business Wire The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies October 15, 2021 Companies working on sorely needed Covid treatments are innovating to keep up. Via Investor's Business Daily AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021 October 14, 2021 From AbCellera Biologics Inc. Via Business Wire Why AbCellera Biologics Stock Jumped 19.4% Last Month October 07, 2021 Despite last month's gains, the biotech stock is now down roughly 61% year to date. Via The Motley Fool AbCellera, Everest Medicines Team Up To Develop 10 Therapeutic Antibodies September 23, 2021 AbCellera Biologics Inc (NASDAQ: ABCL) and Everest Medicines Limited have entered into a multi-year collaboration and license agreement to discover... Via Benzinga The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data September 23, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 22) Acceleron Pharma Inc. (... Via Benzinga Exposures COVID-19 Cramer's Advice On Ulta Beauty, Laredo Petroleum And More September 23, 2021 On CNBC's "Mad Money Lightning Round," Jim Cramer advised a viewer to buy more Ulta Beauty Inc (NASDAQ: ULTA). He likes the stock very much. Cramer doesn't like... Via Benzinga AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies September 22, 2021 From AbCellera Biologics Inc. Via Business Wire A Day Of Huge Market Moves September 21, 2021 It was a day of huge market moves and several reporting companies. Trudeau won but did not get a parliamentary majority. Via Talk Markets Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19 September 21, 2021 From AbCellera Biologics Inc. Via Business Wire 15 Stocks Moving in Friday's Pre-Market Session September 17, 2021 Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) rose 42% to $3.21 in pre-market trading. AbCellera Biologics Inc. (NASDAQ: ABCL) rose 18% to $23.35 in pre-market trading.... Via Benzinga AbCellera Stock Is Moving Higher After Expanded Use Nod For Lilly-Partnered COVID-19 Antibody September 17, 2021 The FDA has expanded the Emergency Use Authorization (EUA) for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in... Via Benzinga Exposures COVID-19 Product Safety The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold September 17, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Bicycle Therapeutics plc (... Via Benzinga Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19 September 16, 2021 From AbCellera Biologics Inc. Via Business Wire Why AbCellera Biologics Stock Jumped 7% on Wednesday September 15, 2021 The company's drug-development technology is starting to attract attention. Via The Motley Fool Exposures COVID-19 AbCellera Shares Are Moving Higher On Licensing Pact With Moderna September 15, 2021 AbCellera Biologics Inc (NASDAQ: ABCL) has entered into a research collaboration and license agreement with Moderna Inc (NASDAQ: MRNA) for antibodies for... Via Benzinga AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines September 15, 2021 From AbCellera Biologics Inc. Via Business Wire AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets September 13, 2021 From AbCellera Biologics Inc. Via Business Wire AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference September 10, 2021 From AbCellera Via Business Wire A Weak Week September 10, 2021 Chinese car-maker Nio appears to have been able to weather the Beijing crackdown on foreign listed firms better than later entrants. Via Talk Markets Here's Why AbCellera Biologics Stock Gained 10.6% Last Month September 04, 2021 Even with its recent gains, the biotech stock is down roughly 53.4% in 2021's trading. Via The Motley Fool Why AbCellera Biologics Stock Was Up More Than 17% on Friday August 13, 2021 The biopharma company's second quarter was better than expected. The future looks pretty bright, too. Via The Motley Fool 78 Biggest Movers From Friday August 16, 2021 Gainers PharmaCyte Biotech, Inc. (NASDAQ: PMCB) shares jumped 43.4% to close at $3.27. PharmaCyte Biotech recently reported closing of $15-million public offering. Flora Growth... Via Benzinga AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript August 13, 2021 ABCL earnings call for the period ending June 30, 2021. Via The Motley Fool Topics Earnings Exposures Financial 53 Stocks Moving In Friday's Mid-Day Session August 13, 2021 Gainers BIOLASE, Inc. (NASDAQ: BIOL) shares climbed 30.9% to $0.8270 after the company reported better-than-expected Q2 sales. The company said it continues to experience demand... Via Benzinga AbCellera Reports Q2 2021 Business Results August 12, 2021 From AbCellera Biologics Inc. Via Business Wire < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.